Russell W Jenkins MD PhD
Hematologic Oncology, Melanoma
Associate Professor of Medicine
Join to View Full Profile
Medical Univ Of S Carolina# 171Charleston, SC 29425
Phone+1 843-792-1414
Dr. Jenkins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Russell Jenkins is an oncology specialist based in Boston, MA, with subspecialties in hematologic oncology and melanoma. He completed his fellowship in hematology and medical oncology at Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute from 2014 to 2018. His earlier training includes an internal medicine internship and residency at Massachusetts General Hospital. Dr. Jenkins earned his M.D. and Ph.D. in 2012 from the Medical University of South Carolina. His expertise includes immunotherapy and melanoma, with several publications focusing on therapeutic strategies and challenges in oncology.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2018
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2013 - 2014- Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 2012 - 2013
Medical University of South CarolinaClass of 2012
Certifications & Licensure
SC State Medical License 2025 - 2027
MA State Medical License 2015 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Design of a potent interleukin-21 mimic for cancer immunotherapy.Jung-Ho Chun, Birkley S Lim, Suyasha Roy, Michael J Walsh, Gita C Abhiraman
Science Immunology. 2025-09-26 - LRP2 Expression in Melanoma Is Associated With a Transitory Cell State, Increased T Cell Infiltration, and Is Upregulated by IFNy Signaling.Martin Q Rasmussen, Marie L Bønnelykke-Behrndtz, Camilla Merrild, Ida Tvilling, Julie N Christensen
Pigment Cell & Melanoma Research. 2025-09-01 - Intratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity.Taral R Lunavat, Lisa Nieland, Sanne M van de Looij, Alexandra J E M de Reus, Charles P Couturier
Molecular Therapy. 2025-08-20
Journal Articles
- Tumor Innate Immunity Primed by Specific Interferon-Stimulated Endogenous RetrovirusesScott Rodig, Ewa Sicinska, Thanh Uyen Barbie, David Allen Barbie, Russell William Jenkins, Ravindra Uppaluri, Rohit Thummalapalli, Jacob Sands, Nature
Press Mentions
Research Spotlight: Key Insights into the Roles and Regulation of CD38 in T Cell DysfunctionJune 27th, 2025- Study Identifies TBK1 as Key to Overcoming CAR T ResistanceJanuary 9th, 2025
- Research Spotlight: Factors Contributing to Treatment Resistance in CAR T Therapies for Solid TumorsJanuary 9th, 2025
- Join now to see all
Grant Support
- Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunityMASSACHUSETTS GENERAL HOSPITAL2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
